Abatacept and cardiovascular risk in rheumatoid arthritis: update
Cardiovascular events (CVEs), such as myocardial infarction, stroke, and sudden cardiac death, which are due to the early development and rapid progression of atherosclerosis, are one of the main causes of mortality in rheumatoid arthritis (RA). Traditional risk factors (TRFs) and immunoinflammatory...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-01-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/796 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Cardiovascular events (CVEs), such as myocardial infarction, stroke, and sudden cardiac death, which are due to the early development and rapid progression of atherosclerosis, are one of the main causes of mortality in rheumatoid arthritis (RA). Traditional risk factors (TRFs) and immunoinflammatory mechanisms underlying the pathogenesis of these diseases are shown to be responsible for atherosclerosis and its clinical manifestations in RA. Since the key role in the development of atherosclerosis and related CVEs in RA is played by chronic inflammation and autoimmune disorders, effective anti-inflammatory therapy occupies an important place in the prevention of the latter. The review gives an update on the effect of abatacept on overall mortality and CVEs, TRFs for cardiovascular disease, and the clinical and subclinical manifestations of atherosclerosis in RA. |
|---|---|
| ISSN: | 1996-7012 2310-158X |